Eliglustat tartrate, miglustat, imiglucerase, velaglucerase or a combination of these for the treatment of Gaucher disease: a review of clinical effectiveness and safety
CADTH
Record ID 32012000040
English
Authors' recommendations:
Limited evidence supports the use of enzyme replacement for Type 1 Gaucher disease and shows no additional benefit of combination with substrate reduction treatment. The evidence is insufficient to draw conclusions regarding the safety and efficacy of substrate reduction treatment for Type 1 Gaucher disease.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.cadth.ca/media/pdf/htis/dec-2011/RC0312-000%20Gaucher%20Disease%20final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Enzyme Inhibitors
- Glucosylceramidase
- Drug Therapy, Combination
- Enzyme Replacement Therapy
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.